Tarsus Pharmaceuticals Inc (TARS) Key Ratios
$83.90
As on 03-Sep-2026 13:35EDT
Market cap
$3,149 Mln
Revenue (TTM)
$606 Mln
P/E Ratio
--
P/B Ratio
9.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 7.32 | 69.41 | 105.17 | 179.47 | 61.35 |
| EBIT | -90.22 | 24.43 | 54.63 | 16.33 | -244.25 |
| Net Profit | -166.27 | 8.80 | 49.48 | 14.19 | -248.65 |
| EPS | -163.59 | 10.97 | 53.58 | 18.98 | -205.55 |
| Book Value | -- | -- | 37.85 | 2.24 | 0.38 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -276.95 | -217.51 | -6.19 | -12.28 | -58.87 |
| Net Margin
| -- | -136.01 | -7.67 | -- | -- |
| Return on equity
| -49.31 | -38.15 | -13.47 | -23.39 | -54.83 |
| Return on Capital
| -41.30 | -32.94 | -- | -18.10 | -44.09 |
| Return on Assets
| -35.07 | -28.72 | -6.77 | -14.14 | -35.97 |
| Debt to Equity (x)
| -- | -- | 0.21 | 0.27 | 0.32 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
-18.10
|
-44.09
|
-61.73
|
-32.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-13.47
Higher than Peers by 26.93
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-13.47
|
-23.39
|
-54.83
|
-69.71
|
-34.53
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-6.77
Higher than Peers by 24.20
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-6.77
|
-14.14
|
-35.97
|
-55.09
|
-30.53
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-6.19
Higher than Peers by 77.42
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-6.19
|
-12.28
|
-58.87
|
-759.71
|
-232.53
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-7.67
Higher than Peers by 85.00
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-7.67
|
-14.72
|
-63.16
|
-778.89
|
-247.05
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
105.17
Higher than Peers by 51.22
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
105.17
|
1.47
|
9.49
|
-0.32
|
-0.55
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
54.63
Higher than Peers by 55.43
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
54.63
|
48.54
|
18.74
|
-120.80
|
-335.89
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
49.48
Higher than Peers by 56.78
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
49.48
|
42.52
|
14.97
|
-118.86
|
-349.06
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
53.58
Higher than Peers by 38.93
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
53.58
|
0.48
|
0.30
|
-0.76
|
-2.61
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
1.76
Higher than Peers by 11.94
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
1.76
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.21
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
0.21
|
0.27
|
0.32
|
0.15
|
0.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
--
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.20
Lower than Peers by 2.61
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
3.20
|
3.85
|
4.42
|
6.93
|
14.61
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
3.17
Lower than Peers by 2.52
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
3.17
|
3.82
|
4.39
|
6.85
|
14.30
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-4.11
Lower than Peers by 2.03
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-4.11
|
-6.20
|
-14.46
|
-41.10
|
-29.08
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
16.21
Lower than Peers by 2.93
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
16.21
|
19.30
|
26.27
|
101.53
|
13.88
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.88
Higher than Peers by 0.82
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
0.88
|
0.96
|
0.57
|
0.07
|
0.13
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
54.69
|
65.66
|
222.91
|
25.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
41.61
|
81.54
|
902.15
|
34,506.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
262.63
|
648.02
|
2,667.72
|
1,597.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
-166.32
|
-500.82
|
-1,542.66
|
32,935.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
-52.74
|
-18.48
|
-4.76
|
-6.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
9.11
Higher than Peers by 3.93
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
9.11
|
10.20
|
9.51
|
3.28
|
1.95
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-3.23
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
-3.23
|
-59.31
|
-18.00
|
-3.41
|
-3.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3,149
Higher than Peers by 3,003
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
3,149
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|